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Hypercholesterolemia is a risk factor for the development of hypertrophic cardiomyopathy. Nevertheless,
there are few studies aimed at determining the effects of dietary compounds on early or mild cardiac
hypertrophy associated with dyslipidemia. Here we describe left ventricular (LV) hypertrophy in 12
week-old Apo E/ hypercholesterolemic mice. The LV end diastolic posterior wall thickness and overall
LV mass were signiﬁcantly increased in Apo E/ mice compared with wild type (WT) controls.
Fractional shortening, LV end diastolic diameter, and hemodynamic parameters were unchanged from
WT mice. Oral low dose quercetin (QCN; 0.1 mmol QCN/kg body weight for 6 weeks) signiﬁcantly reduced
total cholesterol and very low density lipoprotein in the plasma of Apo E/ mice. QCN treatment also
signiﬁcantly decreased LV posterior wall thickness and LV mass in Apo E/ mice. Myocardial geometry
and function were unaffected in WT mice by QCN treatment. These data suggest that dietary
polyphenolic compounds such as QCN may be effective modulators of plasma cholesterol and could
prevent maladaptive myocardial remodeling.
& 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-SA license. Introduction
While left ventricular (LV) hypertrophy is generally regarded as
an adaptive response to chronic pressure or volume overload, it is
also a gateway to pathogenesis and heart failure. Speciﬁcally,
concentric hypertrophy is an early remodeling event that often
precedes myocardial dilatation, progression to eccentric hypertro-
phy, and global pump failure. Several studies show that hyperch-
olesterolemia itself is independently associated with mild LVB.V.
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Open access under CC BY-NC-SAconcentric hypertrophy and increased LV mass in humans [1,2],
underscoring a role for dyslipidemia in myocardial remodeling.
Although some of the mechanisms contributing to these events
have been elucidated, safe interventions with minimal side effects
that prevent or diminish early remodeling events are scant.
Hypercholesterolemic Apo E / mice have substantially ele-
vated triglycerides and increased total plasma cholesterol, and
spontaneously develop atherosclerosis [3]. It has been shown that
these mice exhibit increased LV mass at 6 weeks of age in the
absence of hemodynamic stress [4], further suggesting that
hyperlipidemia may be an early initiator of cardiac remodeling.
Therefore, dietary or other therapeutic interventions that have the
potential to decrease plasma lipids are of particular interest for
prevention of cardiac hypertrophy. For example, the dietary
polyphenol quercetin (QCN) which is present in broccoli, onions,
grapes, and wine [5] has been shown to prevent hypertrophy of
cultured myocytes in response to angiotensin [6] and to lower
blood pressure and attenuate aortic constriction-induced cardiac
hypertrophy in rats [7]. Other polyphenolic compounds such as license. 
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system [8–10]. Taken together with data showing that dietary
intake of polyphenols decreases plasma cholesterol in both
humans and animals [11–13], polyphenols appear to have a
generally beneﬁcial effect on the cardiovascular system[10]. Never-
theless, there are relatively few reports based on the effects of
orally administered polyphenols such as QCN on the heart under
conditions of chronic hypercholesterolemia.
In the present study we elected to use QCN as single poly-
phenolic because of its previously reported beneﬁcial effects on
the cardiovascular system and its potential to serve as the basis for
the development of more potent and effective therapeutics
[14–17]. Therefore, we hypothesized that QCN treatment could
diminish the early cardiac remodeling processes that occur during
hypercholesterolemia. In this study, we examined the effects of
low dose QCN on plasma cholesterol and cardiac geometry and
function in Apo E / and wild-type (WT) mice. Our ﬁndings
suggest that dietary intake of polyphenolics such as QCN may be a
safe and effective means to prevent or decrease hypercholester-
olemia and its associated cardiac structural changes that could
lead to maladaptive remodeling and further functional defects.Table 1
Accumulation of quercetin (QCN) and its derivative, methyl-QCN (Met-QCN) in WT
mouse plasma after oral consumption of gelatin pellets containing QCN.
Time after gavage, (min) QCN (nmol/L) Met-QCN (nmol/L)
30 111.47712.03 23.5875.61
60 65.9076.81 10.3372.35
90 22.8671.25 2.6970.42
Liqueﬁed quercetin pellets were administered by gavage, and the mouse plasma
was collected at different time points after feeding. Concentrations of the
compounds in the plasma were measured by reverse-phase liquid chromatogra-
phy-mass spectrometry. Data are presented as the mean7SEM, N¼5.Materials and methods
Reagents. All chemicals were purchased from Calbiochem (San
Diego, CA), BioMol (Plymouth Meeting, PA) or Sigma-Aldrich-Fluca
(St.Louis, MO). All primary antibodies were obtained from Abcam
Inc (Cambridge, MA).
Animal treatments. Six-week old wild-type (C57BL/6, WT) or
Apo E / (Apoetm1unc) mice were obtained from Jackson Labora-
tories (Bar Harbor, Maine) and fed a standard mouse pellet diet
(Ralston Purina Diet) and water ad libitum for 1 week. For the
following 6 weeks, QCN was administered as gelatin pellets
prepared by mixing ﬂavored gelatin solution (25% w/v) at 37 1C
with QCN solution in DMSO to a ﬁnal concentration of QCN 0.1%
(v/v). Control groups received the pellets without QCN. All mice
were maintained at constant humidity (6075%), temperature
(2471 1C), and light cycle (6AM to 6PM). All protocols were
approved by the Institutional Animal Care and Use Committee at
the University of Alabama at Birmingham and were consistent
with The Guide for the Care and Use of Laboratory Animals
(USDHHS, NIH publication no 86-23, 1996).
Plasma QCN analyses. After bolus gavage of QCN (equivalent to
one feeding), plasma samples were acquired at various time points
by retro-orbital bleeding and by cardiac puncture. They were
treated with a Helix pomati preparation (Sigma, St, Louis, MO) to
hydrolyze glucuronide and sulfate conjugates. In brief, phe-
nolphthalein glucuronide, 4-methylumbelliferyl sulfate, and chry-
sin were added as internal standards to each plasma sample before
hydrolysis with 400 U of ß-glucuronidase and aryl sulfatase in
150 mmol/L ammonium acetate buffer, pH 5, for 16 h at 37 1C.
The samples were extracted with ethyl acetate, then evaporated to
dryness, and ﬁnally reconstituted in 80% aqueous methanol.
LC-MS/MS analyses of plasma QCN and methylated-QCN were
performed using a system consisting of a model SIL-HT refriger-
ated Shimadzu auto sampler and HPLC instrument (Shimadzu
Scientiﬁc Instruments, Inc. Columbia, MD), and an API 4000 mass
spectrometer (Applied Biosystems/MDS Sciex, Concord, Ontario,
Canada). Chromatography was carried out on a reversed-phase
Thermo C18 Gold column (502.0 mm i.d.) pre-equilibrated with
0.1% formic acid. The mobile phase consisted of two eluents,
solvent A (water containing 0.1% formic acid) and solvent B
(acetonitrile containing 0.1% formic acid) with a ﬂow rate of
0.5 ml/min. The total run time was 7 min. Initially, the starting
solvent was 30% B and went up to 100% B over the ﬁrst 4 min. Thesystem was returned to the initial 30% B condition over 6 min. The
column efﬂuent was introduced into the mass spectrometer using
electrospray ionization (ESI) in the negative ion mode. Nitrogen
was used as nebulizer, and curtain gas. The source temperature
and collision energy were 300 1C and -30 eV, respectively. For
multiple reaction monitoring (MRM) experiments, the mass tran-
sitions m/z 301/151 (quercetin), m/z 315/300 (methyl quercetin),
m/z 315/151 (methyl quercetin) and m/z 253/143 (chrysin) were
used. Chrysin was used as internal standard. The LC-MS-MS
system was controlled by BioAnalyst 1.4.1 software. The quantiﬁ-
cation of quercetin and methyl quercetin was based on a calibra-
tion curve over the concentration range 1–10 μmol/L. The assay
method for quantiﬁcation was demonstrated to be speciﬁc, with
lower limit of quantiﬁcation of 1 nmol/L.
Analysis of the lipid proﬁles in mouse plasma. Blood was
collected from anesthetized animals during sacriﬁce by retro-
orbital bleeding. Total plasma cholesterol levels were determined
colorimetrically using a commercial kit (Inﬁnity cholesterol
reagent; Sigma, St. Louis, MO). Plasma lipoprotein cholesterol
proﬁles were analyzed by the chromatographic method described
in [18].
Echocardiography and measurement of blood pressure. Animals
were anesthetized using isoﬂuorane (1–2%) and their body weight
was measured. Analysis of LV parameters by two-dimensional
B-mode, M-mode and PW-Doppler mode echocardiography was
performed non-invasively using an echocardiography high resolu-
tion imaging system VEVO 770 equipped with a 30 MHz transdu-
cer (Visual Sonics, Toronto, Canada). To monitor arterial blood
pressure (BP), the non-invasive device Coda 2 (Kent Scientiﬁc
Corp.; Torrington, CT) was used. Five acclimatization cycles were
performed prior to measurement of BP followed by 15 cycles of
measurements of the systolic and diastolic pressure. Mean arterial
pressure (MAP) was calculated using the equation: MAP¼2/3
Pdias+1/3 Psys. Measurements were carried out over 3 days until
a stable baseline was obtained.
Statistical analysis of data. Results of the echocardiography
measurements are presented as the mean7standard error (SEM)
for 12 animals per phenotype and treatment group. Signiﬁcant
differences were assessed using one-way analysis of variance
(ANOVA). Intergroup comparisons were analyzed using Student-
Newman-Kuels post hoc test with statistical signiﬁcance set at
po0.05.Results
In the course of the study, WT and Apo E / mice were fed the
control or the QCN-containing diets for 6 weeks. Daily consumption
of QCN by animals during the 6 week treatment period was
approximately 0.1 mmol QCN/kg body weight. For the validation of
QCN absorption into the blood, solubilized gelatin pellets were fed to
WT mice (N¼5) by gavage and the concentration of QCN derivatives
was measured in the mouse plasma by mass-spectrometry at various
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Fig. 1. Plasma cholesterol proﬁles of wild type and ApoE / mice fed control and
QCN-supplemented diets: Lipoprotein fractions of total plasma cholesterol were
separated using fast performance liquid chromatography (FPLC). Panel A: Repre-
sentative plasma cholesterol lipoprotein proﬁles for the experimental mouse
groups: WT control (solid line), WT+QCN (dotted line), ApoE/ control (dashed
line) and ApoE/+ QCN (dash-dot line). Peak a: VLDL; peak b: IDL/LDL; peak c:
LDL/HDL1; peak d: HDL. Panel B: Quantitative analysis of individual lipoprotein
peaks from the plasma cholesterol proﬁle. Solid bars indicate the amount of VLDL,
hatched bars represent LDL-HDL1 in WT or IDL-LDL in ApoE/ , and empty bars
correspond to the HDL fraction. N¼6 per group. Data are presented as the
mean7SEM. n,nnpo0.05 for the VLDL fraction when compared to WT. †po0.05
for the LDL-HDL1/IDL-LDL and #.##po0.05 for the total plasma cholesterol when
compared to WT.
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containing pellets, plasma QCN levels reached readily detectable
levels that decreased linearly with time (R2¼0.99; Table 1). QCN
was not detectable (o0.1 nmol/L) in untreated animals. The methy-
lated form of QCN, Met-QCN, which is a metabolite of free QCN, had
similar pharmacokinetics, decreasing with time in the plasma
(Table 1). These data conﬁrm that oral intake of QCN increases
systemic QCN levels for a signiﬁcant period of time.
Separation of the total cholesterol from the plasma of WT and
Apo E/ mice, fed the control or QCN-diet, by fractions, was
performed using FPLC. The resulting chromatograms are presented
as Fig. 1A. In agreement with previous reports and as expected [3],
Apo E / mice displayed severe hypercholesterolemia: the
amount of total cholesterol in Apo E/ control mice was 6-fold
higher than WT. A QCN-dependent decrease in VLDL (peak a) was
observed in the total plasma cholesterol of Apo E / mice. The
difference between the chromatograms of WT and Apo E/ was
attributed to intermediate lipoprotein fractions: IDL-LDL fraction(peak b) in Apo E/ animals and LDL-HDL1 fraction (peak c) in
WT mice. Speciﬁcally, VLDL and IDL-LDL fractions were signiﬁ-
cantly increased in ApoE / animals with respect to WT controls.
Moreover, high density lipoprotein (HDL) was decreased in Apo
E / mice compared with WT mice. Dietary QCN treatment for six
weeks decreased circulating VLDL in ApoE/ animals by 30%
but did not affect levels of IDL-LDL and HDL. (Fig. 1A and B).
Treatment with QCN had no effect on plasma cholesterol fractions
in WT mice.
Apo E / mouse echocardiographic measurements showed no
signiﬁcant changes in LV end diastolic diameter (LVEDD), but
demonstrated signiﬁcant increases in LV posterior wall diameter
(LVPWd) and decreased LVEDD/LVPWd ratios when compared
with WT controls (Figs. 2 and 3). Moreover, overall LV masses
were also increased in Apo E/ mice (Table 2). LV fractional
shortening and systolic, diastolic, and mean arterial blood pres-
sures were not signiﬁcantly different when compared with WT
controls (Table 2). Therefore, unlike Apo E/ mice at 24 weeks of
age and older which have relatively high arterial blood pressures
[19,20], the 12 week-old Apo E / mice showed no indication of
derangements of vascular tone or blood pressure. Taken together,
these data suggest that hypercholesterolemia alone could promote
a mild myocardial concentric hypertrophy in the absence of
hypertension.
Body weight was increased in the Apo E / group relative to
controls and was not altered by QCN treatment (Table 2). Treat-
ment with QCN, however, signiﬁcantly decreased LVPWd in Apo
E / mice and restored LVEDD/LVPWd ratios to control values
(Figs. 2 and 3). Furthermore, QCN treatment prevented the
increases in LV mass that were observed in Apo E / mice fed
vehicle alone. QCN did not affect heart rate or fractional short-
ening in Apo E/ mice or WT controls (Table 2). Taken together,
these data demonstrate that Apo E/ mice display an early, mild
concentric hypertrophy that is independent of hemodynamic
stress and is ameliorated by QCN treatment.Discussion
Polyphenolic compounds have several purported beneﬁcial
cardiovascular effects and have been shown to decrease oxidative
stress, reduce or prevent growth of atherosclerotic plaques, inhibit
platelet aggregation, decrease blood pressure, improve vascular
reactivity, and decrease plasma lipids and lipoproteins [21].
In general, QCN has a beneﬁcial effect on the cardiovascular
system, and has been shown to prevent cardiac remodeling in
severe models of cardiac hypertrophy [7]. Although other studies
have shown that Apo E / mice even at 6 weeks of age
demonstrate increased myocardial mass [4], the study described
herein is the ﬁrst to demonstrate a concentric hypertrophy that
develops seemingly due to hypercholesterolemia alone. This ﬁnd-
ing is particularly important because hypercholesterolemia is a
major contributor to the mild concentric hypertrophy that occurs
in humans [1,2], emphasizing a need for therapeutic interventions
to prevent or diminish the early myocardial structural changes
that could potentially lead to hypertrophic cardiomyopathy. The
development of left ventricular hypertrophy is progressive and
one of the commonest risk factors for cardiovascular mortality.
Importantly, the risk for developing cardiac hypertrophy is asso-
ciated with the metabolic syndrome, increased LDL to HDL ratio
and unfavorable fatty acid proﬁle suggesting that intervention
with low dose QCN could be potentially beneﬁcial [2,22]. Recently,
it has been suggested that polyphenolics may have beneﬁt in
lessening the pathological effects of the metabolic syndrome [23].
Interestingly, we found that low dose dietary QCN treatment
prevents hypertrophy of the LV posterior wall in Apo E / mice.
LVEDD
LVPWd
LVEDD
LVEDD LVEDD
Control +QCN
WT
WT
ApoE-/-
ApoE-/-
Control +QCN
Fig. 2. Two-dimensional echocardiographic images of the left ventricle in WT and Apo E/ mice fed control and QCN-supplemented diets: Panel A: Representative B-mode
images of the LV in the experimental animal groups. Panel B: Representative M-mode images of the LV. Arrows indicate LV diameters and LV posterior wall dimensions in
diastole (LVEDD and LVPWd, respectively).
E. Ulasova et al. / Redox Biology 1 (2013) 381–386384The molecular mechanisms by which QCN prevents hypertrophy
in this mouse model are unknown. Since hypercholesterolemia
alone has been suggested to play a causative role in the etiology ofcardiac hypertrophy [1,2], we suggest that the QCN-dependent
decrease in cardiac hypertrophy in this study can be ascribed to
the decrease in plasma lipids. Recent studies suggest that QCN
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Fig. 3. Group data of echocardiographic measurements taken from hearts of WT
and ApoE/ mice fed control and QCN-supplemented diets: M-mode images of
the LV of WT and ApoE / mice on control and QCN diet were obtained using
echocardiography. Parameters of LV geometry were measured directly using the
resulting images. Panel A: LVEDD. Panel B: LVPWd. Panel C: ratio between LVEDD
and LVPWd. N¼12 in each group. Data are presented as the mean7SEM. npo0.05
compared to WT-controls (one-way ANOVA).
Table 2
Parameters of cardiac function measured in WT and ApoE/ mice fed control diets
or diets with QCN supplementation.
Animal group Wild Type Wild Type
+QCN
Apo E / Apo E /
+QCN
Body weight, (g) 22.3570.31 23.1270.37 25.4470.64n 25.3170.63n
Heart rate, BPM 439713 442714 449713 45379
Systolic BP 14673 15273 16076 15077
Diastolic BP 11573 11673 12676 11477
Mean arterial BP 12573 12873 13776 12677
LV mass
(corrected)
81.4173.72 87.073.74 92.4273.95n 88.1473.42
LV FS 0.3070.02 0.2870.02 0.2870.01 0.2870.01
n po0.05 (n¼12) compared to WT (W; one-way ANOVA).
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macrophages and decreased atherosclerotic lesions [14,16]. Several
polyphenolic compounds, including those found in grapes [12], wine
[24], chocolate [25], and olive oil [26], decrease blood lipids and seemto have a general beneﬁcial effect on the cardiovascular system.
Indeed, we observed a 25% decrease in total plasma cholesterol and
a 30% decrease in plasma VLDL in Apo E/ mice fed QCN (Fig. 1).
As the most pro-atherogenic lipoprotein, VLDL speciﬁcally has been
shown to promote transformation of macrophages to foam cells [27]
and to induce synthesis of the pro-inﬂammatory cytokines TNF-α and
interleukin-1β [28,29]. The VLDL in the Apo E / mouse model
appears to be aggressively pro-atherogenic, possibly because of pre-
ferential existence of Apo B48 over Apo B100 in its structure [30,31]
and, subsequently an 8-fold higher cholesterol to triglyceride ratio
compared to human VLDL [32]. Therefore, the decrease in circulating
VLDL in Apo E/ mice after QCN intake may reduce inﬂammation
and decrease vascular stress which could play a role in the prevention
of cardiac hypertrophy. It is important to note that the amount of the
orally-given QCN in the present study was 4300-fold smaller
compared to other previously reported in vivo studies on vascular
dysfunction [7,33–35] and is consistent with the average amount of
this polyphenol consumed by humans on the Mediterranean diet [36].
The molecular mechanisms underlying both hypercholesterolemia-
induced cardiac hypertrophy and QCN-mediated improvements in
plasma lipids and preclusion from cardiac remodeling are not known
at present.
Collective anecdotal and epidemiological evidence suggest that a
diet rich in QCN promotes cardiovascular health. The translational
potential of polyphenolics is remains an active area of research with
impact on both dietary recommendations and as a route to more
selective and potent therapeutics [37]. Since QCN is rapidly meta-
bolized it has limited utility as cardiovascular therapeutic but the
pharmacophore can serve as a basis for the development of more
efﬁcacious agents. Interestingly, some more metabolically stable
QCN derivatives have been reported to have beneﬁt in the more
severe form of pressure overload-dependent cardiac failure induced
by aortic banding [15,38]. To conclude, in our study, we demon-
strated that dietary supplementation with the polyphenol QCN
decreases plasma cholesterol and diminishes LV hypertrophy in
young Apo E/ mice. These beneﬁcial effects were achieved with
QCN doses that are comparable to the range attainable by the
Mediterranean diet. These ﬁndings may in part underlie the dietary
anomaly known as the “French Paradox,” and support the concept
that supplementation of the diet with foods or drinks rich in
polyphenols such as QCN could offer cardioprotective beneﬁts.Acknowledgments
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